Literature DB >> 17651934

Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy.

Vincent Ribrag1, Daniel Vanel, Sophie Leboulleux, Jean Lumbroso, Dominique Couanet, Guillaume Bonniaud, Anne Aupérin, Florence Masson, Jacques Bosq, Véronique Edeline, Christophe Fermé, Frédéric Pigneur, Martin Schlumberger.   

Abstract

PURPOSE: Initial lymphoma staging requires bone marrow assessment in aggressive lymphomas. Bone marrow lymphoma infiltration is routinely assessed by bone marrow biopsy (BMB), considered as the "gold standard". The aim of this study was to compare the performance of BMB, whole-body MRI and PET/CT for evaluation of BM infiltration.
METHODS: Patients with newly diagnosed aggressive lymphoma were evaluated by BMB, MRI and PET/CT. Two radiologists, two nuclear medicine physicians and one pathologist independently assessed the results of the three modalities. Bone was considered as involved if BM was positive or if PET/CT or MRI was positive and if there was a resolution of the abnormal image shown on PET/CT or MRI halfway or at the end of therapy.
RESULTS: Both MRI and PET/CT detected bone marrow lesions in the 9/43 patients, but two patients with multiple lesions had more lesions detected by PET/CT compared to MRI. Among these nine patients, two with an iliac crest lesion detected by both MRI and PET/CT had bone marrow involvement with large-cell lymphoma on histological examination. The other seven patients had focal MRI and PET/CT lesions in areas other than the iliac crest, where the blind BMB was done. The other patients had bone marrow without large-cell lymphoma involvement. In all cases, after lymphoma therapy bone marrow involvement regressed on histological examination, PET and MRI.
CONCLUSION: These preliminary results suggest that non-invasive morphological procedures could be superior to BMB for bone marrow assessment in aggressive lymphomas. Ongoing study is underway to validate these results.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17651934     DOI: 10.1016/j.ejrad.2007.06.014

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  14 in total

Review 1.  FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis.

Authors:  Hugo J A Adams; Thomas C Kwee; Bart de Keizer; Rob Fijnheer; John M H de Klerk; Rutger A J Nievelstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-27       Impact factor: 9.236

2.  The diagnostic value of FDG-PET cannot be judged by iliac bone marrow biopsy.

Authors:  G Cheng
Journal:  Br J Radiol       Date:  2012-08       Impact factor: 3.039

3.  Can diffusion-weighted whole-body MRI replace contrast-enhanced CT for initial staging of Hodgkin lymphoma in children and adolescents?

Authors:  Rodrigo Regacini; Andrea Puchnick; Flavio Augusto Vercillo Luisi; Henrique Manoel Lederman
Journal:  Pediatr Radiol       Date:  2018-01-23

4.  Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients.

Authors:  Gang Cheng; Wengen Chen; Wichana Chamroonrat; Drew A Torigian; Hongming Zhuang; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-20       Impact factor: 9.236

5.  Whole-body MRI for initial staging of paediatric lymphoma: prospective comparison to an FDG-PET/CT-based reference standard.

Authors:  Annemieke S Littooij; Thomas C Kwee; Ignasi Barber; Claudio Granata; Malou A Vermoolen; Goya Enríquez; József Zsíros; Shui Yen Soh; Bart de Keizer; Frederik J A Beek; Monique G Hobbelink; Marc B Bierings; Jaap Stoker; Rutger A J Nievelstein
Journal:  Eur Radiol       Date:  2014-02-23       Impact factor: 5.315

6.  Characterizing bone marrow involvement in Hodgkin's lymphoma by FDG-PET/CT.

Authors:  Michal Weiler-Sagie; Olga Kagna; Eldad J Dann; Ayelet Ben-Barak; Ora Israel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-26       Impact factor: 9.236

7.  Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation?

Authors:  Pierre Y Salaun; Thomas Gastinne; Caroline Bodet-Milin; Loïc Campion; Pierre Cambefort; Anne Moreau; Steven Le Gouill; Christian Berthou; Philippe Moreau; Françoise Kraeber-Bodéré
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-05       Impact factor: 9.236

8.  Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET.

Authors:  Hugo J A Adams; Thomas C Kwee; Malou A Vermoolen; Bart de Keizer; John M H de Klerk; Judit A Adam; Rob Fijnheer; Marie José Kersten; Jaap Stoker; Rutger A J Nievelstein
Journal:  Eur Radiol       Date:  2013-04-17       Impact factor: 5.315

9.  Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate.

Authors:  Gaetano Paone; Emmanuel Itti; Corinne Haioun; Philippe Gaulard; Jehan Dupuis; Chieh Lin; Michel Meignan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-19       Impact factor: 9.236

Review 10.  Comparison between whole-body MRI and Fluorine-18-Fluorodeoxyglucose PET or PET/CT in oncology: a systematic review.

Authors:  Mario Ciliberto; Fabio Maggi; Giorgio Treglia; Federico Padovano; Lucio Calandriello; Alessandro Giordano; Lorenzo Bonomo
Journal:  Radiol Oncol       Date:  2013-07-30       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.